Get startedLog in
    Picture of Egetis Therapeutics AB (publ) logo

    EGTX — Egetis Therapeutics AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    All News

    Brief: Egetis: FDA Awards Tiratricol Breakthrough Therapy Designation In July 2025

    Picture of Egetis Therapeutics AB (publ) logoEgetis Therapeutics AB (publ)
    18/08/2025 09:49
    Aug 18 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

FDA AWARDS TIRATRICOL BREAKTHROUGH THERAPY DESIGNATION IN JULY 2025

SUBMITS PRE-NDA MEETING REQUEST TO FDA FOR TIRATRICOL

PLANS NDA SUBMISSION FOR TIRATRICOL IN 2025

15 EVALUABLE PATIENTS IN RETRIACT STUDY

Source text: ID:nMFN1PzrQC

Further company coverage: EGTX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Egetis Therapeutics AB (publ)

    See all news